C4 Therapeutics Inc (nasdaq:CCCC) Share Price

Company Profile

Business description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Contact
490 Arsenal Way
Suite 120
WatertownMA02472
USA
T: +1 617 231-0700
https://www.c4therapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
110

Recommended

Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.

Roy Van Keulen | 27 August 2025

Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.

Johannes Faul, CFA | 27 August 2025

Opportunities arise when the market overreacts, and good quality companies are mispriced.

Shani Jayamanne | 27 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,241.10	0.50	-0.01%
CAC 40	7,762.60	18.67	0.24%
DAX 40	24,039.92	6.29	-0.03%
Dow JONES (US)	45,603.07	37.84	0.08%
FTSE 100	9,216.82	38.68	-0.42%
HKSE	24,998.82	202.94	-0.81%
NASDAQ	21,722.52	132.38	0.61%
Nikkei 225	42,828.79	308.52	0.73%
NZX 50 Index	12,903.08	41.24	0.32%
S&P 500	6,501.67	20.27	0.31%
S&P/ASX 200	8,980.00	9.50	0.11%
SSE Composite Index	3,843.60	43.25	1.14%